[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339344-105":59,"doc-detail-339344-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","toxicity-in-older-patients-with-cancer-receiving-immunotherapy-an-observational-study","Toxicity in Older Patients with Cancer Receiving Immunotherapy - An Observational Study","","Checkpoint inhibition is an effective option for many cancers, yet older adults with cancer are highly variable in frailty, cognition, and physical status, making toxicity risk assessment difficult. This observational study evaluates whether clinical frailty relates to immune-related treatment toxicity, hospitalization, and treatment discontinuation in patients aged 70+ receiving checkpoint inhibitors. Frailty was measured with the Geriatric-8 score and WHO status across multiple cohorts; trends link greater frailty with worse outcomes and frequent early discontinuation even at grade 1–2 toxicity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/toxicity-in-older-patients-with-cancer-receiving-immunotherapy-an-observational-study/339344/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/toxicity-in-older-patients-with-cancer-receiving-immunotherapy-an-observational-study/339344.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of the observational study?","Question",{"text":112,"@type":113},"The study investigated the association between clinical frailty and immune-related treatment toxicity, hospitalization, and treatment discontinuation in older patients receiving checkpoint inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was clinical frailty assessed in this study?",{"text":117,"@type":113},"Clinical frailty was assessed using the Geriatric-8 test score and the World Health Organization (WHO) status.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about frailty and toxicity outcomes?",{"text":121,"@type":113},"Patients with more frailty showed consistent trends toward higher odds of toxicity, hospitalization, and treatment discontinuation due to immune-related treatment toxicity.",{"name":123,"@type":110,"acceptedAnswer":124},"What practical implication does the study suggest for older patients?",{"text":125,"@type":113},"The findings support incorporating geriatric screening protocols, since early discontinuation due to immune-related toxicity occurred frequently even among patients with lower toxicity grades (1–2).","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},339344,1790319945,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Drugs & Aging (2024) 41:431–441  \n[https://doi.org/10.1007/s40266-024-01](https://doi.org/10.1007/s40266-024-01)114-z  \nToxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study  \nEstelle Tran Van Hoi1 · Stella Trompet1 · Yara Van Holstein1 · Frederiek Van Den Bos1 · Diana Van Heemst1 ·  \nHenrik Codrington4 · Geert Labots5 · Suzanne Lohman1 · Asli Ozkan2 · Johanneke Portielje2 · Simon P. Mooijaart1 ·  \nNienke A. De Glas2 · Marloes Derks3  \nAccepted: 19 March 2024 / Published online: 10 May 2024 © The Author(s) 2024  \nAbstract  \nBackground Checkpoint inhibition has emerged as an effective treatment strategy for a variety of cancers, including in older adults. However, older patients with cancer represent a heterogenous group as they can vary widely in frailty, cognition, and physical status.  \nObjective This study aims to investigate the association between clinical frailty and immune-related treatment toxicity, hospitalization, and treatment discontinuation due to immune-related treatment toxicity in older patients treated with checkpoint inhibitors.  \nMethods Patients aged 70 years and older treated with checkpoint inhibitors were selected from the TENT study, IMAGINE study, and “Tolerability and safety of immunotherapy study”. Clinical frailty was assessed by the Geriatric-8 test score and World Health Organization (WHO) status. Outcomes were grades 3–5 toxicity, hospitalization, and treatment discontinuation due to toxicity during treatment.  \nResults Of 99 patients included, 22% had comorbidities. While 33% of the patients were considered frail based on an abnormal Geriatric-8 test score of \u003C 15, physical impairments were considered absent in 51%(WHO score of 0) and mild in 40%(WHO score of 1). Despite the limited sample size of the cohort, consistent trends were observed with patients with an abnormal Geriatric-8 test score of \u003C 15 or a higher WHO score of 1 for having higher odds of toxicity [odds ratio (OR) 2.32 (95% CI 0.41–13.02); OR 1.33 (95% CI 0.45–4.17)], treatment discontinuation due to immune-related treatment toxicity [OR 2.25 (95% CI 0.61–8.31); OR 2.18 (95% CI 0.7–6.73)], and hospitalization due to immune-related treatment toxicity [OR 3.72 (95% CI 0.39–35.4); OR 1.31 (95% CI 0.35–4.9)] . Moreover, in a sub-analysis, we observed that the treatment discontinuation due to immune-related treatment toxicity occurred often in patients with grade 1–2 toxicity as well. Conclusions Although not statistically significant, in older patients treated with immunotherapy in a real-life population with cancer, we observed consistent trends towards increased toxicity, hospitalization, and treatment discontinuation with increasing frailty. Larger studies are needed to confirm these exploratory results. Moreover, older patients with a lower toxicity grade 1–2 experienced early treatment discontinuation frequently, suggesting a lower tolerance of toxicity.  \n1 Introduction  \nCancer is highly prevalent in old age and it is estimated that 55% of new cases are diagnosed in people aged over 65 years [1] . Older patients are a heterogeneous group with a large variation in geriatric problems such as impaired cognitive and physical functioning, comorbid diseases, polypharmacy, or frailty. Treatment selection for older patients with cancer can be challenging in the setting of various impairments.  \nExtended author information available on the last page of the article  \nBalancing potential benefits of treatment, such as increased survival or a reduction in symptoms against potential harms (e.g. , adverse effects or risk of complications), can be difficult as the varying complexity in health issues among older patients can affect the ability to endure toxic cancer treatments.  \nGeriatric deficits have been associated with an increased risk of toxicity due to chemotherapy, and with increased mortality [2, 3] . Moreover, in the GAP-70 and GAIN randomized controlled trials, it was demonstrated that when treatmen","cbCairdoNNufil1M","https://ap.wps.com/l/cbCairdoNNufil1M","pdf",907778,11,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Key Points","[{\"question\":\"What was the objective of the observational study?\",\"answer\":\"The study investigated the association between clinical frailty and immune-related treatment toxicity, hospitalization, and treatment discontinuation in older patients receiving checkpoint inhibitors.\"},{\"question\":\"How was clinical frailty assessed in this study?\",\"answer\":\"Clinical frailty was assessed using the Geriatric-8 test score and the World Health Organization (WHO) status.\"},{\"question\":\"What did the results show about frailty and toxicity outcomes?\",\"answer\":\"Patients with more frailty showed consistent trends toward higher odds of toxicity, hospitalization, and treatment discontinuation due to immune-related treatment toxicity.\"},{\"question\":\"What practical implication does the study suggest for older patients?\",\"answer\":\"The findings support incorporating geriatric screening protocols, since early discontinuation due to immune-related toxicity occurred frequently even among patients with lower toxicity grades (1–2).\"}]","Toxicity in Older Patients with Cancer Receiving Immunotherapy - An Observational Study | PDF",1790029729,28]